Skip to main content

4 Result(s)

within Keval Chandarana Remove this filter

and

  1. Article

    Open Access

    Correction to: Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization

    A correction to this paper has been published: https://doi.org/10.1007/s41030-021-00165-6

    Dominique Hubert, Christophe Marguet, Jacques Benichou… in Pulmonary Therapy (2021)

    Download PDF (126 KB) View Article

  2. Article

    Open Access

    Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization

    Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that has demonstrated clinical benefits in phase 3 trials. We report results from a real-world study (BRIO) to assess the e...

    Dominique Hubert, Christophe Marguet, Jacques Benichou… in Pulmonary Therapy (2021)

    Download PDF (522 KB) View Article

  3. Article

    Open Access

    Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States

    Ivacaftor was first approved in 2012 for the treatment of a select population of individuals with cystic fibrosis (CF), a rare, life-shortening genetic disease. Reductions in healthcare resource utilization (H...

    Teja Thorat, Lisa J. McGarry, Krutika Jariwala-Parikh, Brendan Limone… in Pulmonary Therapy (2021)

    Download PDF (593 KB) View Article

  4. No Access

    Article

    Shedding pounds after going under the knife: Metabolic insights from cutting the gut

    Keval Chandarana, Rachel L Batterham in Nature Medicine (2012)